Centrum 7/6  banner

Novavax COVID-19 vaccine

FDA grants EUA for Novavax COVID-19 vaccine

FDA grants EUA for Novavax COVID-19 vaccine

GAITHERSBURG, Md. — Novavax announced this week that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18

FDA committee recommends authorizing Novavax COVID-19 vaccine

FDA committee recommends authorizing Novavax COVID-19 vaccine

WASHINGTON — An independent advisory committee voted on Tuesday overwhelmingly in favor of authorizing biotech company Novavax’s protein-based COVID-19 vaccine. The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 21-0 with one abstention, in favor of granting Emergency Use Authorization status for the traditional style vaccine. The final decision will be made by

PP_1170x120_10-25-21